EDOXABAN TOSYLATE | DAIICHI SANKYO INC | ||
EQ 15MG BASE,EQ 30MG BASE,EQ 60MG BASE | |||
Yes | No | ||
2028-Mar-28 | 2020-Jan-08 | ||
None | None | ||
None | No | ||
SAVAYSA is a factor Xa inhibitor indicated: • To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant. |
0 | 1 | 0 |
Total Other Developers | 6 |
---|
Drugs with Suitability | No |
---|
EQ 15MG BASE | ** | ** | - | - | - |
EQ 30MG BASE | ** | ** | - | - | - |
EQ 60MG BASE | ** | ** | Up | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
Yes | 0 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com